Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.

Authors

Eoghan Malone, I

Eoghan Ruadh Malone

Princess Margaret Hospital, Toronto, ON, Canada

Eoghan Ruadh Malone , Jeremy Howard Lewin , Lisa Wang , Susan Lau , Robert James Hamilton , Aaron Richard Hansen , Keith Jarvi , Wenjiang Zhang , Eric Xueyu Chen , Philippe L. Bedard

Organizations

Princess Margaret Hospital, Toronto, ON, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada, Murray Koffler Urologic Wellness Centre, Joseph and Wolf Lebovic Health Complex, Toronto, ON, Canada, Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Research Funding

Other
Department of Medical Oncology and Hematology Grant (Internal Princess Margaret Hospital)

Background: Cisplatin is highly curative treatment for testicular cancer. Most survivors develop azoospermia immediately after cisplatin with recovery expected in 50% at 2 years and 80% at 5 years. Platinum is a heavy metal that can be detected at low levels in serum many years after treatment, however, it is not known whether platinum also persists in semen and if platinum persistence in semen is associated with impaired fertility. Methods: Testicular cancer survivors previously treated with cisplatin were enrolled, relapsed disease treated with salvage chemotherapy was excluded. Semen samples were collected to assess semen quality. Repeat semen collections were performed if azoo- or oligospermia was noted. Serum and semen Platinum levels were determined using HPLC-tandem mass spectrometry. DNA Fragmentation Index (DFI) was measured. Results: From 11/2017 to 12/2019, 38 pts (median age 32 years; range: 19-52; median BSA 2.03; range: 1.81-2.61) were enrolled, 31 were treated with 3 cycles of Bleomycin, Etoposide, Cisplatin. Median cumulative cisplatin dose was 300 mg/m2 (range: 274-404). Median serum platinum concentration was 0.1 ng/mL (range: 0-22.6) at a median of 11 months (range 0.5-36) post treatment completion. Median semen platinum concentration was 0.5 ng/mL (range: 0.2-28.7) at a median of 14 months (range: 1.3-40) post treatment completion. Semen platinum levels were higher in semen than in blood drawn at the same time (p = 0.03). Semen platinum levels were associated with time from last cisplatin dosing (r = -0.34; p = 0.09) but not cumulative cisplatin dose (r = -0.10, p = 0.63). Sperm concentration was correlated with time from last cisplatin dosing (r = 0.58, p < 0.001) but not with semen platinum level (r = -0.15, p = 0.46). DFI was associated with time from last cisplatin dosing (r = 0.55, p = 0.08) but not with semen platinum level (r = -0.32, p = 0.33). In 4 pts with serial semen samples available, semen platinum level decreased with time, sperm concentration and motility increased. Conclusions: Platinum can be detected in semen in long-term testicular cancer survivors at higher levels than matched blood samples. Our preliminary findings may have important implications for reproductive health of survivors of advanced testicular cancer, further studies are needed to assess the relationship between platinum persistence in semen and recovery of fertility post chemotherapy.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Germ Cell/Testicular

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5056)

DOI

10.1200/JCO.2020.38.15_suppl.5056

Abstract #

5056

Poster Bd #

125

Abstract Disclosures